- Home
- ATXS vs IMNM Comparison
ATXS vs IMNM Comparison
Compare ATXS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- IMNM
- Stock Information
- Founded
- ATXS 2008
- IMNM 2006
- Country
- ATXS United States
- IMNM United States
- Employees
- ATXS N/A
- IMNM N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- ATXS Health Care
- IMNM Health Care
- Exchange
- ATXS Nasdaq
- IMNM Nasdaq
- Market Cap
- ATXS 516.4M
- IMNM 585.5M
- IPO Year
- ATXS 2015
- IMNM 2020
- Fundamental
- Price
- ATXS $7.50
- IMNM $9.99
- Analyst Decision
- ATXS Strong Buy
- IMNM Strong Buy
- Analyst Count
- ATXS 5
- IMNM 5
- Target Price
- ATXS $25.60
- IMNM $28.60
- AVG Volume (30 Days)
- ATXS 368.6K
- IMNM 881.8K
- Earning Date
- ATXS 03-03-2025
- IMNM 11-13-2024
- Dividend Yield
- ATXS N/A
- IMNM N/A
- EPS Growth
- ATXS N/A
- IMNM N/A
- EPS
- ATXS N/A
- IMNM N/A
- Revenue
- ATXS N/A
- IMNM $10,129,000.00
- Revenue This Year
- ATXS N/A
- IMNM N/A
- Revenue Next Year
- ATXS N/A
- IMNM N/A
- P/E Ratio
- ATXS N/A
- IMNM N/A
- Revenue Growth
- ATXS N/A
- IMNM N/A
- 52 Week Low
- ATXS $6.96
- IMNM $8.97
- 52 Week High
- ATXS $16.90
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- ATXS 29.58
- IMNM 40.28
- Support Level
- ATXS $7.29
- IMNM $9.24
- Resistance Level
- ATXS $7.95
- IMNM $11.06
- Average True Range (ATR)
- ATXS 0.42
- IMNM 0.74
- MACD
- ATXS -0.08
- IMNM -0.06
- Stochastic Oscillator
- ATXS 15.25
- IMNM 31.78
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.